Summary
Global Markets Direct’s, ‘Ischemia Reperfusion Injury - Pipeline Review, H2 2016’, provides an overview of the Ischemia Reperfusion Injury pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury
- The report reviews pipeline therapeutics for Ischemia Reperfusion Injury by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Ischemia Reperfusion Injury therapeutics and enlists all their major and minor projects
- The report assesses Ischemia Reperfusion Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Amyndas Pharmaceuticals LLC
Angion Biomedica Corp.
Biomedica Management Corporation
Bolder Biotechnology, Inc.
Corline Biomedical AB
Curatis Pharma GmbH
Erimos Pharmaceuticals, LLC
Gilead Sciences, Inc.
Ischemix, Inc.
Kowa Company, Ltd.
LG Life Science LTD.
Omeros Corporation
Opsona Therapeutics Limited
Orexo AB
Pharming Group N.V.
PledPharma AB
Prolong Pharmaceuticals, LLC
Proteo, Inc.
Prothix BV
Recordati S.p.A.
Stealth BioTherapeutics Inc.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Ischemia Reperfusion Injury Overview 8
Therapeutics Development 9
Pipeline Products for Ischemia Reperfusion Injury - Overview 9
Pipeline Products for Ischemia Reperfusion Injury - Comparative Analysis 10
Ischemia Reperfusion Injury - Therapeutics under Development by Companies 11
Ischemia Reperfusion Injury - Therapeutics under Investigation by Universities/Institutes 13
Ischemia Reperfusion Injury - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Ischemia Reperfusion Injury - Products under Development by Companies 18
Ischemia Reperfusion Injury - Products under Investigation by Universities/Institutes 20
Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development 22
Amyndas Pharmaceuticals LLC 22
Angion Biomedica Corp. 23
Biomedica Management Corporation 24
Bolder Biotechnology, Inc. 25
Corline Biomedical AB 26
Curatis Pharma GmbH 27
Erimos Pharmaceuticals, LLC 28
Gilead Sciences, Inc. 29
Ischemix, Inc. 30
Kowa Company, Ltd. 31
LG Life Science LTD. 32
Omeros Corporation 33
Opsona Therapeutics Limited 34
Orexo AB 35
Pharming Group N.V. 36
PledPharma AB 37
Prolong Pharmaceuticals, LLC 38
Proteo, Inc. 39
Prothix BV 40
Recordati S.p.A. 41
Stealth BioTherapeutics Inc. 42
Ischemia Reperfusion Injury - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Target 44
Assessment by Mechanism of Action 47
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
AER-271 - Drug Profile 54
AM/AMBP-1 - Drug Profile 55
ANV-6L15 - Drug Profile 56
APP-103 - Drug Profile 57
BB-3 - Drug Profile 58
BBT-059 - Drug Profile 62
C1 esterase inhibitor (recombinant) - Drug Profile 63
CMX-2043 - Drug Profile 71
CRX-526 - Drug Profile 74
Curaglutide - Drug Profile 75
Des-Asp Angiotensin 1 - Drug Profile 76
Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury - Drug Profile 77
elamipretide - Drug Profile 78
EP-80317 - Drug Profile 85
GS-459679 - Drug Profile 86
hemin (human) - Drug Profile 87
KN-93 - Drug Profile 88
LH-021 - Drug Profile 89
mangafodipir trisodium - Drug Profile 90
MG-53 - Drug Profile 91
mirococept - Drug Profile 93
Monoclonal Antibodies to Inhibit MMP-8 for Renal Ischemia and Shock - Drug Profile 94
Monoclonal Antibody for Ischemia Reperfusion Injury - Drug Profile 95
Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease and Kidney Transplantation - Drug Profile 96
Monoclonal Antibody to Inhibit IL-16 for Renal Ischemia Reperfusion Injury - Drug Profile 98
NecX - Drug Profile 99
Neutrolide - Drug Profile 100
NP-202 - Drug Profile 101
Oligonucleotide for Oncology and Cardiovascular Diseases - Drug Profile 102
OMS-721 - Drug Profile 103
OPN-305 - Drug Profile 109
pitavastatin NP - Drug Profile 111
PRO-02 - Drug Profile 112
R-190 - Drug Profile 113
Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischemia - Drug Profile 115
Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 116
Recombinant Protein Slit2 to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis - Drug Profile 117
Recombinant Protein to Antagonize EPHA4 for ALS, Acute Spinal Cord Injury and Ischemia Reperfusion Injury - Drug Profile 118
Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile 119
Recombinant Proteins to Agonize PTCH1 for Ischemia Reperfusion Injury - Drug Profile 120
Recombinat Protein to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury - Drug Profile 121
Renaparin - Drug Profile 122
Sanguinate - Drug Profile 123
Small Molecule to Agonize Adenosine Receptor for Neurodegenerative Diseases and Ischemia Reperfusion Injury - Drug Profile 125
Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile 126
Small Molecules for Ischemia Reperfusion Injury - Drug Profile 127
Small Molecules for Ischemia Reperfusion Injury - Drug Profile 128
Small Molecules for Ischemia Reperfusion Injury - Drug Profile 129
Small Molecules for Ischemia Reperfusion Injury and Inflammation - Drug Profile 130
Small Molecules to Activate Protein Kinase B for Ischemia Reperfusion Injury - Drug Profile 131
Small Molecules to Activate SGK-1 for Ischemic Reperfusion Injury - Drug Profile 132
Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile 133
Synthetic Peptides for Ischemia Reperfusion Injury - Drug Profile 134
Synthetic Peptides for Oncology, Immunology and Cardiovascular Disorders - Drug Profile 135
terameprocol - Drug Profile 136
tiprelestat - Drug Profile 138
TMS-007 - Drug Profile 142
UCF-101 - Drug Profile 143
UWA-TAT - Drug Profile 144
VCP-746 - Drug Profile 145
Ischemia Reperfusion Injury - Dormant Projects 146
Ischemia Reperfusion Injury - Discontinued Products 150
Ischemia Reperfusion Injury - Product Development Milestones 151
Featured News & Press Releases 151
Appendix 162
Methodology 162
Coverage 162
Secondary Research 162
Primary Research 162
Expert Panel Validation 162
Contact Us 162
Disclaimer 163
List of Tables
Number of Products under Development for Ischemia Reperfusion Injury, H2 2016 13
Number of Products under Development for Ischemia Reperfusion Injury - Comparative Analysis, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Number of Products under Development by Companies, H2 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2016 18
Comparative Analysis by Late Stage Development, H2 2016 19
Comparative Analysis by Clinical Stage Development, H2 2016 20
Comparative Analysis by Early Stage Development, H2 2016 21
Products under Development by Companies, H2 2016 22
Products under Development by Companies, H2 2016 (Contd..1) 23
Products under Investigation by Universities/Institutes, H2 2016 24
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 25
Ischemia Reperfusion Injury - Pipeline by Amyndas Pharmaceuticals LLC, H2 2016 26
Ischemia Reperfusion Injury - Pipeline by Angion Biomedica Corp., H2 2016 27
Ischemia Reperfusion Injury - Pipeline by Biomedica Management Corporation, H2 2016 28
Ischemia Reperfusion Injury - Pipeline by Bolder Biotechnology, Inc., H2 2016 29
Ischemia Reperfusion Injury - Pipeline by Corline Biomedical AB, H2 2016 30
Ischemia Reperfusion Injury - Pipeline by Curatis Pharma GmbH, H2 2016 31
Ischemia Reperfusion Injury - Pipeline by Erimos Pharmaceuticals, LLC, H2 2016 32
Ischemia Reperfusion Injury - Pipeline by Gilead Sciences, Inc., H2 2016 33
Ischemia Reperfusion Injury - Pipeline by Ischemix, Inc., H2 2016 34
Ischemia Reperfusion Injury - Pipeline by Kowa Company, Ltd., H2 2016 35
Ischemia Reperfusion Injury - Pipeline by LG Life Science LTD., H2 2016 36
Ischemia Reperfusion Injury - Pipeline by Omeros Corporation, H2 2016 37
Ischemia Reperfusion Injury - Pipeline by Opsona Therapeutics Limited, H2 2016 38
Ischemia Reperfusion Injury - Pipeline by Orexo AB, H2 2016 39
Ischemia Reperfusion Injury - Pipeline by Pharming Group N.V., H2 2016 40
Ischemia Reperfusion Injury - Pipeline by PledPharma AB, H2 2016 41
Ischemia Reperfusion Injury - Pipeline by Prolong Pharmaceuticals, LLC, H2 2016 42
Ischemia Reperfusion Injury - Pipeline by Proteo, Inc., H2 2016 43
Ischemia Reperfusion Injury - Pipeline by Prothix BV, H2 2016 44
Ischemia Reperfusion Injury - Pipeline by Recordati S.p.A., H2 2016 45
Ischemia Reperfusion Injury - Pipeline by Stealth BioTherapeutics Inc., H2 2016 46
Assessment by Monotherapy Products, H2 2016 47
Number of Products by Stage and Target, H2 2016 49
Number of Products by Stage and Mechanism of Action, H2 2016 52
Number of Products by Stage and Route of Administration, H2 2016 55
Number of Products by Stage and Molecule Type, H2 2016 57
Ischemia Reperfusion Injury - Dormant Projects, H2 2016 150
Ischemia Reperfusion Injury - Dormant Projects (Contd..1), H2 2016 151
Ischemia Reperfusion Injury - Dormant Projects (Contd..2), H2 2016 152
Ischemia Reperfusion Injury - Dormant Projects (Contd..3), H2 2016 153
Ischemia Reperfusion Injury - Discontinued Products, H2 2016 154
List of Figures
Number of Products under Development for Ischemia Reperfusion Injury, H2 2016 13
Number of Products under Development for Ischemia Reperfusion Injury - Comparative Analysis, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Number of Products under Investigation by Universities/Institutes, H2 2016 17
Comparative Analysis by Clinical Stage Development, H2 2016 20
Comparative Analysis by Early Stage Products, H2 2016 21
Assessment by Monotherapy Products, H2 2016 47
Number of Products by Top 10 Targets, H2 2016 48
Number of Products by Stage and Top 10 Targets, H2 2016 48
Number of Products by Top 10 Mechanism of Actions, H2 2016 51
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 51
Number of Products by Top 10 Routes of Administration, H2 2016 54
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 54
Number of Products by Molecule Types, H2 2016 56
Number of Products by Stage and Top 10 Molecule Types, H2 2016 56
